Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Boston Therapeutics Inc (OTCQB:BTHE)

0.1381
Delayed Data
As of Feb 10
 -0.0269 / -16.33%
Today’s Change
0.03
Today|||52-Week Range
0.58
+26.19%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$5.4M

Company Description

Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products include therapeutic modules such as BTI320, Ipoxyn, and Oxyfex. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Manchester, NH.

Contact Information

Boston Therapeutics, Inc.
1750 Elm Street
Manchester New Hampshire 03104
P:(603) 935-9799
Investor Relations:
(603) 512-6593

Employees

Shareholders

Individual stakeholders41.56%
Mutual fund holders--
Other institutional--

Top Executives

David PlattChairman, CEO, CFO & Treasurer
Louise GelinasDirector-Business Operations
Benjamin RivnayChief Scientist
Eric HobermanManager-Clinical Affairs
Anthony Don SquegliaSecretary & Vice President-Investor Relations